SCHEMBL737002

SCHEMBL737002

CCN1C(=Cc2ccc3ccccc3[n+]2CC)C=Cc2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A3 O75751 2/20 1.00
SLC22A2 O15244 1/20 1.00
SLC22A1 O15245 1/20 1.00
NQO2 P16083 1/20 1.00
MEN1 O00255 14/20 0.98
KMT2A Q03164 14/20 0.98
HTT P42858 11/20 0.98
POLB P06746 11/20 0.98
MAPT P10636 11/20 0.98
RAB9A P51151 10/20 0.98
ALDH1A1 P00352 10/20 0.98
LMNA P02545 9/20 0.98
SMN1; SMN2 Q16637 9/20 0.98
NPSR1 Q6W5P4 7/20 0.98
PKM P14618 6/20 0.98
RECQL P46063 4/20 0.98
ALPG P10696 3/20 0.98
S1PR2 O95136 2/20 0.98
BLM P54132 4/20 0.76
THRB P10828 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13619260 1.00 SLC22A3 (1.00) SLC22A3SLC22A2SLC22A1NQO2MEN1
Bromide SCHEMBL3389494 1.00 SLC22A3 (1.00) SLC22A3SLC22A2SLC22A1NQO2MEN1
SCHEMBL29378931 1.00 SLC22A3 (1.00) SLC22A3SLC22A2SLC22A1NQO2MEN1
SCHEMBL29832895 1.00 SLC22A3 (1.00) SLC22A3SLC22A2SLC22A1NQO2MEN1
SCHEMBL3978997 1.00 SLC22A3 (1.00) SLC22A3SLC22A2SLC22A1NQO2MEN1
Bromide SCHEMBL3389493 1.00 SLC22A3 (1.00) SLC22A3SLC22A2SLC22A1NQO2MEN1
Iodide SCHEMBL8859608 0.99 SLC22A3 (1.00) SLC22A3SLC22A2SLC22A1NQO2MEN1
Iodide SCHEMBL29462337 0.99 SLC22A3 (1.00) SLC22A3SLC22A2SLC22A1NQO2MEN1
Hydrochloric Acid SCHEMBL4107666 0.99 MEN1 (1.00) SLC22A3SLC22A2SLC22A1NQO2MEN1
Iodide SCHEMBL4779860 0.99 SLC22A3 (1.00) SLC22A3SLC22A2SLC22A1NQO2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250093360-A1 DNA BASED SENSORS GEORGE MASON UNIVERSITY 2025-03-20 US claimed
US-20230118682-A1 MODIFIED J-AGGREGATES AND CONJUGATES THEREOF GEORGE MASON UNIVERSITY (US) 2023-04-20 US claimed
EP-3573749-B1 PHOTOLUMINESCENT HYBRID ORGANIC/INORGANIC MATERIALS AND METHOD FOR PREPARING SAME CENTRE NAT RECH SCIENT (FR) 2023-04-12 EP claimed
US-20200158647-A1 ENCAPSULATED DYE COATED NOBLE METAL NANOPARTICLES WITH INCREASED SURFACE ENHANCED RAMAN SCATTERING PROPERTIES AS CONTRAST AGENTS ZAMECNIK COLIN R (US) 2020-05-21 US claimed
EP-2932243-B1 ENCAPSULATED DYE COATED NOBLE METAL NANOPARTICLES WITH INCREASED SURFACE ENHANCED RAMAN SCATTERING PROPERTIES AS CONTRAST AGENTS ZAMECNIK COLIN R (US) 2020-05-13 EP claimed
US-20170319719-A1 J-Aggregate Forming Nanoparticle UNIVERSITY HEALTH NETWORK (CA) 2017-11-09 US claimed
US-20150359912-A1 J-Aggregate Forming Nanoparticle UNIVERSITY HEALTH NETWORK (CA) 2015-12-17 US claimed
EP-2950827-A1 J-AGGREGATE FORMING NANOPARTICLE University Health Network (CA) 2015-12-09 EP claimed
US-20150316481-A1 ENCAPSULATED DYE COATED NOBLE METAL NANOPARTICLES WITH INCREASED SURFACE ENHANCED RAMAN SCATTERING PROPERTIES AS CONTRAST AGENTS ZAMECNIK COLIN R (US) 2015-11-05 US claimed
EP-2932243-A1 ENCAPSULATED DYE COATED NOBLE METAL NANOPARTICLES WITH INCREASED SURFACE ENHANCED RAMAN SCATTERING PROPERTIES AS CONTRAST AGENTS Zamecnik, Colin R. (US) 2015-10-21 EP claimed
EP-2024741-A2 DETECTING PRESENCE OF SILVER-CONTAINING ANTIMICROBIAL AGENTS EASTMAN KODAK COMPANY (US) 2009-02-18 EP claimed
US-20080096193-A1 Methods and compositions for detecting polynucleotides INVESTIGEN, INC. 2008-04-24 US claimed
WO-2007139703-A2 DETECTING PRESENCE OF SILVER-CONTAINING ANTIMICROBIAL AGENTS EASTMAN KODAK COMPANY (US) 2007-12-06 WO claimed
US-20070275472-A1 METHOD FOR DETECTING PRESENCE OF SILVER-CONTAINING ANTIMICROBIAL AGENTS EASTMAN KODAK COMPANY 2007-11-29 US claimed
US-20070231821-A1 Methods and compositions for detecting polynucleotides INVESTIGEN, INC. 2007-10-04 US claimed
EP-0684463-B1 Temperature indicating device and composition for use therein 3M INNOVATIVE PROPERTIES CO (US) 2007-09-05 EP claimed
US-20070098802-A1 Organic nanoparticles and associated methods HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. 2007-05-03 US claimed
WO-2005088786-A1 ORGANIC POLARITON LASER THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2005-09-22 WO claimed
US-20050195873-A1 Organic polariton laser AIR FORCE OFFICE OF SCIENTIFIC RESEARCH 2005-09-08 US claimed
US-20050195874-A1 Organic polariton laser UNITED STATES AIR FORCE 2005-09-08 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070231821-A1 Methods and compositions for detecting polynucleotides POLN, POLRMT, POLH SLC22A3 2902/4885SLC22A2 2749/4885SLC22A1 3117/4885
US-20080096193-A1 Methods and compositions for detecting polynucleotides POLN, POLRMT, POLH SLC22A3 3121/4885SLC22A2 2939/4885SLC22A1 3235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.